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Sphingolipids, especially ceramide, sphingosine, and 
sphingosine-1-phosphate, play essential roles in cell signal-
ing (1–5). They are modulators of various aspects of biol-
ogy and pathology, including aging and cancer. In cancer, 
sphingolipids regulate tumor initiation, progression, me-
tastasis, and drug resistance (1, 3, 5–9). Excess ceramide 
leads to cancer cell death, reduced growth, and senes-
cence, and may serve as a real-time predictive marker for 
radiation treatment response (6, 7, 9, 10). On the other 
hand, sphingosine-1-phosphate promotes inflammation, 
metastasis, proliferation, vasculogenesis, and drug resis-
tance (4, 5, 8, 11).
Mainly three pathways generate ceramide, namely the 
de novo pathway, the salvage pathway, and the SM cycle 
(12–14). Several enzymes are involved in the SM cycle, 
including the SM synthases (SMSs) (SMS1 and SMS2) 
that catalyze the conversion of ceramide to SM, and several 
SMases that hydrolyze SM to generate ceramide (13, 15–18). 
Acid SMase, encoded by SM phosphodiesterase (Smpd1), is 
a lysosomal enzyme the deficiency of which is associated 
with Niemann-Pick disease (19, 20). Four mammalian neu-
tral SMases (nSMases) have been identified so far, among 
which nSMase2 (encoded by Smpd3) appears to be the pre-
dominant nSMase in various tissues and associated patho-
physiologies (12, 15, 21). Mice deficient in nSMase2 have 
multiple developmental defects, including dwarfism and 
delayed puberty, attributed to hypothalamic pituitary defi-
ciency (16–18). nSMase2 is implicated in diverse cellular 
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functions, including inflammation and pathophysiology of 
pulmonary, circulatory, cardiac, and neurological systems 
(15). It is also implicated in cancers, such as leukemia, 
breast cancer, and liver cancer (22, 23). A recent genome-
wide study indicates that Smpd3 is a potential repressor of 
hepatocellular carcinoma (HCC) (24).
Sphingolipids play essential roles in stem cell and cancer 
stem-like cell (CSC) biology (2, 25–29). CSCs, also termed 
cancer-initiating cells or tumor-initiating cells, are a subpopu-
lation of cells in the tumor that possess stem cell character-
istics (30, 31). They are derived from either reactivation of 
dormant progenitor cells or dedifferentiation of somatic cells 
(30–32). Mounting evidence has demonstrated that CSCs 
contribute significantly to tumor initiation, metastasis, treat-
ment resistance, and relapse in many cancer types, including 
liver cancer (30, 31). Thus, identifying and targeting CSCs is 
a promising new strategy for cancer therapy (33). Signal 
transducer and activator of transcription 3 (Stat3) is a key 
transcription factor in maintaining mouse embryonic stem 
cell self-renewal and CSC stemness (34–37). Stat3 is phos-
phorylated and activated by Janus kinases (30). The activated 
Stat3 translocates into the nucleus and binds to promoters of 
stemness genes, including the liver CSC marker protein, 
CD133, leading to their expression (30, 35).
We report here the potential function of sphingolipids 
in liver tumor development using the nSMase2-deficient 
(fragilitas ossium, fro/fro) mouse line (38, 39). This mouse 
line was discovered in a random-bred stock of mice after 
treatment with the chemical mutagen, tris(1-aziridinyl)
phosphine-sulphine (40), which caused a deletion in the 
Smpd3 gene leading to loss of enzyme activity (38). These 
mice show similar phenotypes as nSMase2 knockout mice 
generated through gene-targeting approaches (16–18). In 
our study, liver tumors were observed in 27.3% of aged 
male fro/fro mice (9 of 33), accompanied by increased pro-
liferation and apoptosis. Lipidomics studies demonstrate a 
marked increase of C16-SM, C18-SM, C24:1-SM, C16-ceramide, 
and dihydro (dh)C16-ceramide in the tumor tissue. The 
number of CSCs was increased in fro/fro liver tumors, as 
determined by quantitative (q)PCR and immunocyto-
chemistry of marker genes CD133 and/or EpCAM. Inter-
estingly, CD133(+) cells were labeled for high levels of SM 
and ceramide. Furthermore, fro/fro liver tumors exhibited 
a significant increase of ceramide synthase (CerS)5 expres-
sion and lipid droplet (LD) content, suggesting that the 
lack of nSMase2 was associated with a compensatory 
upregulation of sphingolipid and neutral lipid synthesis, 
which may play a role in CSC proliferation/survival and 
tumor formation in the fro/fro mouse.
MATERIALS AND METHODS
Materials
Oil Red O (ORO), propylene glycol, and fluoroshield supple-
mented with DAPI were from Sigma-Aldrich (St. Louis, MO). 
Anti-Ki67 was from Novocastra (Buffalo Grove, IL). Lysenin and 
anti-lysenin antibody were from Peptide Institute, Inc. (Osaka, 
Japan). Anti-CD133 was from EMD Millipore (Billerica, MA). 
Anti-phosphorylated (p)Stat3 and anti-total (t)Stat3 were from 
Cell Signaling Technology (Danvers, MA). Anti-ceramide rabbit 
IgG was generated in our laboratory as described previously (41). 
Fluorophore-conjugated secondary antibodies were from Jackson 
ImmunoResearch Laboratories (West Grove, PA). The in situ 
TUNEL fluorescence staining kit was from Roche (Indianapolis, IN).
Animals
The nSMase2-deficient (fro/fro) mouse line (C3H and C57Bl6 
mixed background), carrying a deletion in the Smpd3 gene, was a 
gift from Dr. Christophe Poirier, Indiana University, Indianapolis, 
IN (38, 39). These mice were maintained in the Laboratory Animal 
Service facility of the Medical College of Georgia at Augusta Univer-
sity according to the National Institutes of Health’s Guide for the Care 
and Use of Laboratory Animals. All procedures were approved by the 
Augusta University Institutional Animal Care and Use Committee.
Methods
Tissue collection. Tumor and adjacent normal tissues were col-
lected immediately after surgery by either snap-freeze in 80°C 
or fixation with 4% PFA. Frozen tissues were never allowed to 
thaw after initial freezing until used for further experiments. 
Fixed tissues were either embedded in optimal cutting temperature 
medium or paraffin for sectioning. H&E staining and RNA analysis 
were used for quality control of the integrity of the samples.
Histology, immunohistochemistry, and confocal laser microscopy. For 
histology studies, paraffin-embedded tissues were sectioned into 
10 m slices and stained by H&E in the Electron Microscopy and 
Histology Core Laboratory at Augusta University (directed by Dr. 
Sylvia B. Smith). For immunohistochemistry, frozen or paraffin 
sections were immunolabeled with the antibodies listed and 
images taken using a Zeiss LSM 510 upright or a Zeiss LSM 780 
inverted confocal laser scanning microscope equipped with a two 
photon argon laser at 488 nm (Cy2), 543 nm (Cy3), and 633 nm 
(Cy5, Alexa Fluor 647), respectively. LSM 510 Meta 3.2 software 
was used for image acquisition and processing. Samples labeled 
with antibodies against lipids were only PFA-fixed and frozen for 
cryosectioning. Images obtained with secondary antibodies were 
only used as negative controls to correct for background intensity 
of a particular laser channel. Antigen-specific immunolabeling 
was quantified by counting cells that showed signals 2-fold or 
more above background fluorescence. The percentage of Ki67- 
and TUNEL-positive cells was counted at ×400 magnification in at 
least five random fields where tumors existed.
ORO staining. Fixed frozen sections were washed with dis-
tilled water. Excess water was drained and depleted by rinsing 
twice using propylene glycol. ORO was applied and incubated for 
7 min at 60°C. Specimens were destained with 85% propylene 
glycol, rinsed in distilled water, and counterstained using hema-
toxylin. After sufficient washing with water, specimens were 
mounted with aqueous mounting media and microscopic images 
taken using an epifluorescence microscope.
RNA extraction, RT-PCR, and qPCR. RNA was extracted using 
the TriZol reagent (Invitrogen). First strand cDNA was generated 
by the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-
time qPCR was performed using SYBR green/Rox qPCR master 
mix on the CFX96 Touch real-time system (Bio-Rad). The prim-
ers for qPCR were: mCerS5-forward, TAGAGAGCAGCTGAGAG-
GAAGAAGA; mCerS5-reverse, GAACCCAGAGTCTCAAGAGC-
CATGGC; mCD133-forward, CAGCAATCACTGAAATTTGTG; 
mCD133-reverse, ACATCCTCTGAATCCATCCTG; mEpCAM-
forward, TATTTTGAAAAAGATGTGAAG; mEpCAM-reverse, 
ATTA AGCTCTCTGTGGATCTC.
Sphingolipid measurement. Liver tissues were analyzed at the 
Lipidomics Core of the Medical University of South Carolina 
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according to published protocols on a Thermo Fisher TSQ Quan-
tum triple quadrupole mass spectrometer, operating in a multiple 
reaction monitoring positive ionization mode (42). Briefly, similar 
amounts of tissue were homogenized, protein concentration 
determined, aliquots of the homogenates equivalent to 1.5 mg 
protein fortified with internal standards (ISs), and lipids from the 
fortified homogenates extracted twice with 2 ml ethyl acetate, iso-
propanol, and water (60:30:10 v/v/v) solvent. Lipid extracts were 
evaporated and reconstituted in 150 l of 1 mM ammonium for-
mate in 0.2% formic acid in methanol before being subjected to 
LC-MS/MS on the HP1100/TSQ Quantum LC-MS/MS system. 
The samples were gradient-eluted from the BDS Hypersil C8, 150 × 
3.2 mm, 3 m particle size column, with a 1.0 mM methanolic am-
monium formate per 2 mM aqueous ammonium formate mobile 
phase system. Peaks corresponding to the target analytes and ISs 
were collected and processed using the Xcalibur software system. 
Quantitative analysis was based on the calibration curves gener-
ated by spiking an artificial matrix with the known amounts of the 
target analyte synthetic standards and an equal amount of the ISs. 
The target analyte/IS peak area ratios were plotted against analyte 
concentration. The target analyte/IS peak area ratios from the 
samples were similarly normalized to their respective IS and com-
pared with the calibration curves using a linear regression model. 
Results were normalized to lipid phosphate.
Statistics. The statistical significance was calculated using Stu-
dent’s t-test with Excel or one-way ANOVA and Tukey’s post hoc 
test with GraphPad Prism. P < 0.05 was considered significant.
RESULTS
Aged fro/fro male mice show liver tumors
To determine a potential involvement of nSMase2 and 
sphingolipids in hepatic cancer, we analyzed liver tissue in 










fro/+ Male 16–24 0 21 0
fro/fro Female 16–24 0 31 0
fro/fro Male 16–24 9 33 27.3
Fig. 1. Gross and microscopic features of liver tumors in fro/fro mice. A: Tumors were observed in aged male fro/
fro mouse livers. One age-matched fro/+ control (left) and two tumors are shown (right). These tumors contained 
heterogeneous nodules sized from 0.1 to 5 mm. The color of many nodules was pale, suggestive of focal fat ac-
cumulation. Scale bar = 2 mm. B: H&E staining showed two well-defined proliferation nodules within the tumor. 
Scale bar = 200 m. C: Higher magnification of inset  in B. The tumor contains large and vacuolated hepatocytes 
(left). Liver parenchyma was pushed to the side (right). Scale bar = 10 m. D, E: Profound cell hyperplasia 
(arrowheads) (D) and lymphocyte infiltration (arrows) (E) in the tumor. Scale bars = 50 m.
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aged fro/fro mice (38, 39). Spontaneous hepatic tumors 
were observed in 9 out of 33 (27.3%) aged (18–24 months 
old) male fro/fro mouse livers (38) (Table 1, Fig. 1A). The 
phenomenon appeared to be age- and sex-dependent 
because no tumors were detected in young (less than 
10 months old) or in age-matched female (0 of 31) fro/fro 
mice (Table 1). The incidence in aged-matched male con-
trols (fro/+) was also 0% (0 of 21) (Table 1). The liver tu-
mors contained heterogeneous proliferation nodules sized 
0.1–5 mm in diameter (Fig. 1A). The color of many nodules 
was pale, suggestive of focal fat accumulation (Fig. 1A).
H&E staining of the tumor sections revealed many well-
defined proliferation nodules of varying sizes (T1 and T2, 
Fig. 1B). Higher magnification of the inset  in nodule T1 
indicated a clear boundary between the tumor tissue and 
liver parenchyma (Fig. 1C). The hepatocytes within the tu-
mor showed enlarged and vacuolated cytoplasm, suggesting 
fat buildup (Fig. 1C). Pronounced cell hyperplasia (arrow-
heads, Fig. 1D) and penetration of lymphocytes along the 
portal vein (arrow, Fig. 1E) were observed within the tumor.
Enhanced proliferation and apoptosis in fro/fro liver 
tumors
Dysregulated cell proliferation and death is a hallmark 
of cancer (43). We detected the rate of cell proliferation 
and death in the fro/fro liver tumors. The number of Ki67-
positive cells was markedly increased in the tumors when 
compared with normal adjacent tissues (Fig. 2A, C), indi-
cating that cell proliferation was enhanced. On the other 
hand, the number of TUNEL-positive cells was also mark-
edly increased, indicating augmented apoptosis (Fig. 2B, C). 
These results are consistent with clinical findings that, 
although evasion of cell death pathways is a major attribute 
of cancer, as tumor cells grow and exhaust the nutritional 
supply from blood circulation, dead cells remain a com-
mon feature of many malignancies (44, 45).
Increased number of CSCs in fro/fro liver tumors
CSCs contribute to liver carcinogenesis (46–48). The fro/
fro liver tumors contained pockets of proliferating cells 
(Figs. 1D, 2A), which could be due to the existence of CSCs. 
To dissect the cell source of tumor formation, we tested for 
the presence of CSCs in fro/fro liver tumors. RT-PCR and 
qPCR results showed that the message levels of CD133 and 
EpCAM, two markers of liver CSCs (30, 35), were increased 
by 15- and 54-fold, respectively, in fro/fro liver tumors when 
compared with adjacent normal tissues (Fig. 3A, B).
The IL6/JAK/Stat3 pathway is essential for stem cell 
pluripotency and CSC stemness (34–37). Sphingolipids 
have been shown to regulate multiple pluripotency path-
ways, including the Akt/GSK-3 and IL6/JAK/Stat3 path-
ways (3, 49–51). We tested to determine whether nSMase2 
deficiency in fro/fro mice had an effect on these pathways. 
Western blot analysis showed that the pStat3 level when 
normalized to tStat3 was significantly increased in fro/fro 
liver tumors as compared with adjacent normal tissue, indi-
cating that the IL6/JAK/Stat3 pathway was activated in fro/fro 
liver tumors (Fig. 3C, D). However, the Akt/GSK-3 path-
way was not activated (not shown). To further elucidate that 
CSCs were increased in fro/fro liver tumors, we colabeled 
for CD133 and pStat3. Figure 3E shows that there were 
pockets of CD133(+) CSCs in fro/fro liver, which colabeled 
exclusively with pStat3, indicating that the CD133(+) cells 
were pluripotent (Fig. 3E). We could not detect CD133(+) 
or pStat3(+) cells in control (fro/+) liver tissue (Fig. 3E).
Aberrant sphingolipid profile in fro/fro liver tumors
To understand the mechanism of liver tumor formation 
related to sphingolipids, we analyzed the alteration of the 
sphingolipid profile caused by nSMase2 deficiency. nSMase2 
catalyzes SM hydrolysis to generate ceramide. Consistently, 
fibroblasts from fro/fro mice showed accumulation of SM 
(52). Lipidomics (LC-MS/MS) data indicated that the 
major SM species in the liver, C16-, C22-, C24-, and C24:1-SM, 
were slightly upregulated in normal adjacent fro/fro liver 
tissue when compared with age-matched fro/+ controls 
(Fig. 4A and not shown). Although consistent with a previ-
ous report (52), the differences were not statistically signifi-
cant. In contrast, in the fro/fro tumors, the levels of C16- and 
C18-SM and total SM were all significantly increased when 
compared with normal adjacent liver tissues or to age-matched 
Fig. 2. Increased proliferation and cell death in fro/fro liver tu-
mors. A: Proliferation was increased in fro/fro liver tumors as shown 
by Ki67 labeling (green). Con, fro/+ liver tissue; Tumor, fro/fro tu-
mor. Scale bar = 20 m. B: Apoptosis was augmented in fro/fro liver 
tumors, as shown by TUNEL staining (red). Scale bars = 50 m. C: 
Quantification of Ki67- and TUNEL-positive cells in A and B. N = 5. 
*P < 0.05, **P < 0.01.
Liver tumors in nSMase2-deficient mice 799
fro/+ controls (Fig. 4A). In particular, the level of C16-SM 
was increased by more than 4-fold (Fig. 4A).
Surprisingly, total ceramide content was also signifi-
cantly increased in fro/fro liver tumors when compared with 
normal adjacent liver tissues or age-matched fro/+ controls 
(Fig. 4B). The levels of C16 ceramide and dhC16 ceramide, 
especially, were increased by more than 7-fold (Fig. 4B), 
although they were not dominant ceramide species in the 
liver (not shown). In addition, the levels of dhC16- and C24:1-
ceramide were significantly higher in normal adjacent 
tissue of fro/fro liver than control fro/+ liver (Fig. 4B). The 
level of C16-ceramde was increased in fro/fro non-tumor 
tissue, but the difference was not statistically significant 
when compared with fro/+ controls (not shown).
Fig. 3. CSCs in fro/fro liver tumors. A, B: The levels of liver CSC markers CD133 and EpCAM were significantly increased in fro/fro liver tu-
mors shown by RT-PCR (A) and qPCR (B). Con, fro/+ liver tissue; Tumor, fro/fro tumor. C, D: The level of pStat3 was significantly increased 
in fro/fro liver tumors, as shown by Western blot (C) and densitometric quantification (D). E: CD133(+) (green) cells were positive for pStat3 
(red). Scale bar = 20 m.
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To investigate whether accumulation of SM and ceramide 
were associated with CSC formation, we colabeled liver 
tissues with antibodies against CD133, ceramide, and SM 
(pre-incubated by lysenin). CD133 reactivity was located in 
cells that showed strong labeling of SM (Fig. 4C) and 
ceramide (Fig. 4D), while cells with low SM/ceramide label-
ing were CD133(). There were no detectable CD133(+) 
cells or accumulation of SM and ceramide in normal 
adjacent liver tissues and age-matched fro/+ controls, sug-
gesting that accumulation of these two sphingolipids is 
associated with CSC proliferation or survival in liver.
Increased sphingolipid and neutral lipid synthesis in fro/
fro liver tumors
Next, we set out to delineate the potential mechanism of 
increased ceramide synthesis in fro/fro liver tumors by mea-
suring the levels of CerSs, especially of those that generate 
C16-ceramide, which has been shown to exert pro-survival 
functions (53) and was increased the most in fro/fro liver 
tumors (Fig. 4B). Two CerSs catalyze C16-ceramide genera-
tion, CerS5 and CerS6. RT-PCR and qPCR showed that 
CerS5 expression was significantly increased when com-
pared with normal adjacent tissues, while CerS6 was below 
the detection limit (Fig. 5A, B and not shown). These data 
suggest that CerS5 was distinctly upregulated in fro/fro liver 
tumors, likely to compensate for deficiency of nSMase2.
Alterations of sphingolipid metabolism are often associ-
ated with an accumulation of neutral lipids and the forma-
tion of LDs in the liver (54). Recent research has found 
that LD formation contributes to the development of 
tumors and CSCs (55). To further characterize lipid altera-
tions in the tumor, we visualized hepatic LD content using 
ORO staining. Liver tissues from young fro/+ or fro/fro mice 
exhibited little ORO staining (data not shown). Some LD 
accumulation was observed in fro/+ liver tissues from aged 
mice (Fig. 6A), consistent with a previous report that aging 
increases lipogenesis in the liver (56). Notably, the fro/fro 
liver tumors contained a substantially higher amount of LDs 
Fig. 4. Aberrant sphingolipid metabolism in fro/fro liver tumors. A: Lipidomics analyses showed that C16-, 
C18-, and total SM were significantly increased in fro/fro liver tumors. Control animal was fro/+ liver; normal 
adjacent tissue was from fro/fro animals that had tumors. N = 2. *, P < 0.05. B. Lipidomics analyses showed that 
the levels of ceramide, especially C16-, C24-, C24:1-, and total ceramide were increased in fro/fro liver tumors. 
N = 2. *P < 0.05. C: Coimmunolabeling of CD133 and SM. Scale bar = 20 m. D: Coimmunolabeling of CD133 
and ceramide. Scale bar = 20 m.
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(Fig.6C) when compared with the adjacent normal tissue 
(Fig. 6B) or age-matched controls (Fig. 6A). Interestingly, 
the non-tumor tissue of the fro/fro mice (Fig. 6B) exhibited 
less ORO staining than that of aged-matched fro/+ controls 
(Fig. 6A). Figure 6D shows additional low magnification 
ORO images of a fro/fro liver tumor (encircled by green 
arrows), which clearly exhibit the profoundly higher ORO 
staining in fro/fro liver tumor when compared with normal 
adjacent tissues (upper panel and the area outside of green 
arrow, Fig. 6D). Collectively, these data indicate that the 
tumors observed in aged fro/fro mice are associated with 
increased lipid accumulation in contrast to the trend 
observed in non-tumor tissue, where nSMase2 deficiency 
reduces LD biogenesis.
DISCUSSION
Liver cancer is one of the most fatal and common can-
cers worldwide. Although in recent years the occurrence of 
many cancers has decreased, the occurrence rate of liver 
cancer has steadily increased (57, 58). Liver cancers are 
usually detected at a late stage and are highly resistant to 
conventional chemo- and radiotherapy, leading to very 
poor survival rates.
Genome-wide association studies and genetic analyses 
have identified that impaired sphingolipid metabolism is 
common in many cancers, including liver cancer (3, 24, 
59, 60). A recent genome-wide methylation analysis and 
epigenetic unmasking identified nSMase2 (encoded by 
Smpd3) as a tumor suppressor for HCC (24). Overexpres-
sion of nSMase2 reduced cell proliferation by 50% in a HCC 
cell line (24). Conversely, nSMase2 knockdown with small 
hairpin RNA promoted cell invasion and migration in vitro 
and increased tumor formation in vivo (24). However, the 
sphingolipid metabolism affected by nSMase2 and how this 
altered lipid metabolism regulates tumor formation are 
not known.
In the current study, liver tumors were observed in over 
a quarter of aged male fro/fro mice (Table 1, Fig. 1). There 
is no report on tumor formation in nSMase2-deficient ani-
mals, most likely because studies on older mice have not 
been performed. These tumors showed increased prolifera-
tion and apoptosis (Fig. 2), a common feature of many 
malignancies (44, 45). Interestingly, the tumors had an 
increased number of CSCs, which was confirmed by West-
ern blot and immunofluorescence labeling of pStat3, a 
stemness marker (Fig. 3) (34–37). These data indicate that 
CSCs might be a cell source of the origin of the tumors in 
fro/fro livers.
To study the potentially underlying mechanism, we inves-
tigated the sphingolipid metabolism affected by nSMase2 
deficiency in the fro/fro mice. The fro/fro tumors showed a 
profound increase of SM and ceramide levels (Fig. 4), indi-
cating that nSMase2 deficiency induced a significant sphin-
golipid makeover specifically in tumor cells and likely CSCs. 
This assumption is consistent with tumor-specific activation 
of de novo ceramide and SM synthesis (61), possibly as a 
compensatory response to the genetic nSMase2 deficiency. 
Significantly higher levels of ceramides and SM have been 
reported in breast cancer tissue than in normal tissue (61). 
SMS2 overexpression promotes mouse liver steatosis, a ma-
jor contributor to the development of HCC, whereas SMS2 
deficiency has the opposite effect (62). Despite a certain 
level of variation, mounting evidence has demonstrated 
that sphingolipid metabolism, particularly elevation of SM 
and ceramide, has essential functions in cancer develop-
ment (29, 61–66). Importantly, the CSC labeling is concur-
rent with strong labeling for ceramide and SM (Fig. 4C, D), 
suggesting that buildup of these two sphingolipids could be 
a contributing factor for CSC proliferation or survival. This 
is in line with previous findings that changes in SM and 
ceramide metabolism associate with CSC maintenance and 
resistance against apoptosis induction (9, 29, 64).
Expression of CerS5 was distinctly increased in the fro/fro 
liver tumors (Fig. 5), likely accounting for the increase of 
C16- and dhC16-ceramide levels. Previous studies have 
shown that palmitate-induced elevation of C16-ceramide 
promotes LD formation in liver cells (54) and inhibition of 
de novo ceramide synthesis affects liver lipid metabolism 
and LD formation in vivo (67), suggesting that an increase 
of ceramide levels may account for the accumulation of 
LDs in fro/fro tumors (Fig. 6). Aberrant lipid metabolism 
and LD accumulation are associated with liver tumors (68). 
While a small side population of CSCs may already show 
initial alteration of sphingolipid metabolism in normal or 
precancerous tissue, elevation of SM, CerS5, and ceramide 
becomes more significant and profound once they grow 
into a tumor. It is also possible that elevation of SM, CerS5, 
Fig. 5. Aberrant synthesis of sphingolipid in fro/fro liver tumors. A: CerS5 was elevated in fro/fro tumors 
shown by RT-PCR using two sets of samples. CerS2 did not change. Controls (Con) were from normal adjacent 
tissues of fro/fro tumors (Tumor). GAPDH was used as loading control. B: CerS5 was elevated in fro/fro tumors 
shown by qPCR. N = 3. *P < 0.05.
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and C16-ceramide, accumulation of LDs, and activation of 
Stat3 lead to dedifferentiation of mature hepatocytes into 
formation and propagation of CSCs, which then causes tu-
mor formation. These two distinct mechanisms are com-
patible with accumulation of LDs because of the Warburg 
effect, a mitochondrial dysfunction preventing fatty acid 
oxidation in cancer cells (69, 70). This mitochondrial 
damage leads to a compensatory fermentation and the ini-
tiation of dysregulated cell growth, which results in prolif-
eration and propagation of CSCs (69, 71). We will further 
investigate the mechanistic connection between nSMase2 
deficiency, LD formation, and liver tumor growth in future 
studies.
Another question to be investigated is the gender- 
specific development of liver tumors in aged male, but not 
in female, fro/fro mice. This gender-specificity is probably 
linked to the hypothalamus-pituitary-adrenal axis defect 
caused by nSMase2 deficiency. There is evidence that HCC 
is an androgen-sensitive tumor and that sex hormones pro-
mote tumor proliferation (72–75). The pituitary gland of 
the smpd3 mutant mice showed reduced size, and the num-
bers of ACTH-positive, FSH- and LH-positive, and other 
hormone-positive pituicytes were all significantly reduced 
in the nSMase2-deficient mice (16, 17). In addition, our 
studies on nSMse2 inhibition and deficiency on plaque for-
mation in Alzheimer’s disease clearly showed effects in 
male, but not in female, mice (76, 77). Hence, gender- 
specific hormonal effects may underlie the observation that 
only aged male fro/fro mice developed liver tumors. Despite 
these open questions, our study is the first showing that 
Fig. 6. Aberrant LD accumulation in fro/fro liver tumors. A–C: ORO staining of liver lipid LDs in the livers of age-matched fro/+ control 
(A), non-tumor fro/fro (B), and fro/fro liver tumors (C). Scale bars = 5 m. D: Lower magnification images of ORO staining of fro/fro liver 
tumors and normal adjacent tissues. The area encircled by green arrows is tumor. Scale bars = 20 m. Insets are shown in the right panels.
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nSMase2 deficiency is associated with CSC propagation/
survival and liver tumor formation, and will possibly spur 
future studies to understand the function of sphingolipid 
metabolism in age-related liver cancer.
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